In conclusion, the study demonstrates that CAR grafted with PD1 exhibits enhanced antitumor activity with lower cytokine release and no PD1-related off-target toxicity in tumor models that overexpress CD19 and PDL1. This evidence concerns the gene PDCD1 and neoplasm.